Date post: | 16-Apr-2015 |
Category: |
Documents |
Upload: | patel-bhavin |
View: | 229 times |
Download: | 9 times |
Board of Directors
Shri K Raghavendra Rao, Chairman & Managing Director
Shri K Raghavendra Rao has a Bachelors Degree in Commerce from Andhra University and a Post-Graduate Diploma in Management from IIM-Ahmedabad. He is also a member of The Institute of Cost & Works Accountants of India and The Institute of Company Secretaries of India. He is the Founder and Chairman and Managing Director of Orchid. Prior to establishing Orchid, he was associated with leading organisations in India in various capacities. He was singularly responsible for developing a multi-business conglomerate in the Gulf, which included the region’s first ever bulk drugs plant.
Shri S Krishnan, Executive Director - Finance
Shri S Krishnan has been associated with Orchid for around a decade and has been heading the finance function in the last few years. He has a rich and diversified experience of over 24 years in the field of finance and Accounts. He possesses a degree in Bachelor of Science from the University of Madras and is also a member of the Institute of Chartered Accountants of India and the Institute of Company secretaries of India. Shri S Krishnan in addition to his executive responsibilities as a Board member also holds the current role of Chief Financial Officer of the company.
Shri K Biju George, Nominee Director - IDBI
Shri K Biju George has 22 years of vast experience in Project Management and Project Finance. He has a decade long association with premier Financial Institution / Commercial Bank in India; where since last three years, he is in charge of Infrastructure Corporate Group, handling accounts of Kerala & Tamil Nadu. Shri K Biju George also has a vast industrial experience in the field of Projects, Planning & Maintenance in Chemical, Petrochemical & Manufacturing sectors.
Shri Deepak Vaidya
Shri Deepak Vaidya holds a commerce degree from the University of Mumbai and is a fellow member of the Institute of Chartered Accountants, England and Wales. He has been on the Board of Orchid since 1999 and is also a member of the Audit Committee and Remuneration Committee.
Shri Bharat D. Shah
Shri Bharat D. Shah is one of the founder members of HDFC Bank. He has served in various organisations such as Pyrene Company Limited, Bradma India Limited, Technova, Thomas Cook, Citibank and had been an Investment Advisor for Union Bank of Switzerland, Singapore. He is presently the Chairman of HDFC Securities Limited. Shri Bharat Shah is a B.Sc graduate from the Bombay University and holds a Higher National Diploma in Applied Chemistry from London University.
Prof. Bala V. Balachandran
Prof. Bala V. Balachandran is a PhD in Industrial Administration and an MBA from Carnegie Mellon University. He is also a Certified Public Accountant, Certified Management Accountant and Certified Internal Auditor. Currently, he is involved with the Ministry of Corporate Affairs in setting up of the Indian Institute of Corporate Affairs. He is the Founder & Dean of Great Lakes Institute of Management and also the Founder & President of Mumbai Business School in India. Additionally, he is Executive
Professor & Strategy Advisor to the Dean, Bauer College, University of Houston and J. L. Kellogg's Distinguished Professor (Emeritus in service) of Accounting and Information Management, Northwestern University in USA. He was awarded the Padma Shri in 2001.
Management TeamDr. B Gopalan – CSO
Ms. Edna Braganza – Chief Operating Officer – API
Mr. M S Rangesh – Chief Human Resource Officer
Mr. V Vijayendran – Chief Executive – Domestic Formulations
Mr. S Mani - President – Process Research, SH&E and CSR
Dr. R Buchi Reddy – Executive Vice President – Process Research
Mr. P N Deshpande – Executive Vice President – Manufacturing
Dr. Shridhar Narayanan – Executive Vice President – Biology
Mr. S Sridharan – Executive Vice President – IT & IE
Mr. V S Padalkar – Senior Vice President – Engineering & Production
Mr. K V V Raju – Senior Vice President – Technical Operations
Dr. U P Senthil Kumar – Senior Vice President – Process Research
Dr. Shashank Narayanrao Lulay – Senior Vice President – QA
Dr. C V Srinivasan – Senior Vice President – Medicinal Chemistry
Dr. J Surya Kumar – Senior Vice President – Formulation Development
Mr. Deepak M B Nayyar – Vice President – Domestic Formulations
Mr. Gurmeet Singh – Vice President – Commercial
Mr. V C Nagaraj – Vice President – Human Resources
Mr. Sampath Parthasarthy – Vice President – Domestic Formulations
Mr. P Sreenivasa Rao - Vice President – QA & RA
Mr. A Suresh Babu – Vice President – Corporate Affairs
PhilosophyInnovation drives growth. Sensitive to market needs and committed to innovation, here at Orchid we focus on niche product manufacturing platforms, combining cutting-edge technology and the best minds in the business.
Valuing PeopleWe value individuality and creativity. Our unique “People and Process Paradigm” helps achieve the twin objective – emphasis on regulatory and compliance on one hand, while fostering – innovation and creativity on the other.
Peak PerformanceWe seek to build a sustainable organisational eco-system where one is constantly motivated to attain new heights and empowered to discover new avenues for growth.
QualityQuality has always been a strong part of Orchid’s proposition. Our quality initiative covers all aspects including product quality, operational quality, environmental quality and finally a good quality of life for our people.
Harmony with SocietyWe seek to balance environmental impact and economic interest in all our business activities. Committed to the development of the society, culture and economy, we dutifully observe laws; demonstrate high ethical standards and endeavour to preserve the environment.
Vision & Mission
VisionEnriching Lives through Innovation in Healthcare
Mission"Discovery to Delivery"
Orchid is a vertically integrated pharmaceutical company with established research, manufacturing and marketing capabilities across multi-therapeutic domains. We successfully leverage our penchant for science and technology to create niche products and manufacturing platforms leading to attractive growth.
ValuesMost organisations are mostly driven by strategies. We are also driven by values.
Corporate Social Responsibility Respect for the Individual Excellence Innovation Value for Stakeholders
History & Milestones
1992 Orchid Chemicals & Pharmaceuticals Ltd. is established on 1st July and obtains the
Certificate for Commencement of Business. The company undertakes to set up a 100% EOU (export oriented unit) for manufacture of
90 TPA of cephalosporin antibiotics.
1993 Goes public and issues shares, subscribed & paid-up.
1994 Starts commercial production. Receives Good Manufacturing Practice (GMP) Certification.
1996
Sets up a state-of-the-art formulation facility exclusively for manufacture of sterile cephalosporin formulations.
Receives ISO Certification for Quality Systems. Commissions sterile lyophilisation plant.
1997 Becomes the youngest Indian pharmaceutical company to receive the ISO 9002
Certification. Commissions the R&D Centre. Launches a range of new products in the sterile category. Becomes country's largest producer of oral and sterile cephalosporin. Is ranked among the top five producers of cephalosporin APIs.
1998 Orchid Healthcare, the formulations division becomes operational.
1999 Receives ISO Certification for Environment Management Systems.
2000 Acquires a manufacturing plant at Aurangabad. Commissions plant for manufacturing nutraceutials.
2002 Receives the ISO 9001:2000 Certification. Sets up a joint venture alliance with a US-based drug discovery research firm Bexel
Biotechnology Inc, USA (Bexel). Sets up an office in USA. Enters into a joint venture with NCPC to set up a manufacturing joint venture in China.
2003 Acquires domestic formulations company, Mano Pharmaceuticals and enters the chronic
therapy segment. Sets up an office in Russia.
Inaugurates new Corporate Office. Commissions state-of-the-art Good Laboratory Practices (GLP) compliant pre-clinical
facility to support drug discovery. Signs an exclusive pact with Apotex to market select sterile antibiotic dosage forms in
USA. Formulation facilities receive the Therapeutic Goods Administration (TGA) approval.
Enables marketing range of cephalosporin bulk drugs (sterile & non-sterile) and non-cephalosporin formulations in Australia and New Zealand.
European Directorate for the Quality of Medicines (EDQM) & United Kingdom Medicines and Healthcare Regulatory Agency (UK MHRA) successfully inspects API facilities.
Joint venture with Bexel moves its novel anti-diabetic molecule (BLX-1002) into human clinicals.
Aurangabad API facility is awarded ISO 14001 and OHSAS 18001 Certification.
2004 Joint venture with Bexel successfully completes Phase 1 (a) clinical trials on its lead anti-
diabetic molecule (BLX-1002). Joint venture with Bexel successfully completes Phase 1(b) clinical trials on its lead anti-
diabetic molecule (BLX-1002). Signs an agreement with Par Pharmaceuticals to market oral cephalosporin formulations
in US market. Enters into an agreement with Apotex Inc. for an exclusive marketing pact in the
Canadian market. Joint venture with Bexel successfully completes Phase 2(a) trials on its lead anti-diabetic
molecule (BLX-1002). Molecule receives patent clearance from US patent office. Enters into a marketing agreement with Par Pharma for non-penicillin and non-
cephalosporin (NPNC) products. Enters into an agreement with Phoenix for key veterinary injectable product.
2005 Inks pact with Alpharma to market NPNC dosage forms in US & European markets. Enters into a marketing agreement with STADA Pharmaceuticals (USA) for NPNC
products. Receives GLP Certification. Becomes fifth company in India to be certified for its R&D
expertise. His Excellency, the then Hon'ble President of India Dr. A.P.J. Abdul Kalam visits
Orchid's state-of-the-art formulations manufacturing complex located in the SIPCOT Industrial Estate, Irungattukottai, near Sriperumbudur.
Medicinal chemistry labs are commissioned in the New Drug Discovery center. Enters into an agreement with Mayne Pharma (now Hospira) for marketing injectable
antibiotic formulations in selected regulated markets (US, Europe and ANZ).
Enters into a long-term Master Agreement with Pfizer for certain custom research and manufacturing services (CRAMS).
2006 Undertakes structural consolidation of global discovery research. Acquires 100% of US
discovery entity, Bexel Pharmaceuticals. Cephalosporin API and FDF facilities receives UK MHRA approval. Signs deal with Biovitrum in drug discovery field.
2007 UK MHRA approves betalactam API facility located in Aurangabad, near Mumbai. Enters into a licensing and distribution alliance with Actavis to market cephalosporin
formulations in Europe. Forays into the Canadian generic formulations market. Receives Canadian Therapeutic
Product Directorate (TPD) approval for two generic formulations. Enters into a marketing arrangement with a leading distribution house for oral
cephalosporin and non-cephalosporin products. Completes the sterile carbapenem API facility in Aurangabad.
2008 Formulation facilities that manufacture a range of cephalosporin and penicillin injections
approved by the Medicines Control Council (MCC), South Africa. Completes the sterile carbapenem dosage form facility at Irungattukottai, Chennai. Receives the Piperacillin-Tazobactum dossier and ANDS approvals for Australian and
Canadian markets. Sets up a wholly owned subsidiary in Japan called Orchid Pharma Japan K K (Orchid
Japan) to capitalise on the growing Japanese market. Undertakes the development of a Novel Anti-coagulant Drug Candidate from Merck and
invests in Diakron Pharmaceuticals Inc. (Diakron), a US-based drug discovery and development company, which has an exclusive license agreement with Merck for the compound.
Enters into a research collaboration and license agreement with Merck to discover, develop and commercialise molecules essential for the treatment of bacterial and fungal infections.
2009 US FDA approves ANDA for Piperacillin and Tazobactum injection with 6 months
exclusivity.
Orchid inks business transaction agreement with Hospira to transfer the generic injectables formulations dosage form pharmaceutical business for USD 400 million.
2010 Completes business transfer transaction for sale and transfer of its generic injectable
finished dosage forms pharmaceuticals business to Hospira. Collaborates with Alvogen to license and market its eight oral non-antibiotic generic
formulations. Acquires US-based marketing company Karalex Pharma, to strengthen its presence in the
front-end US market and to reach its generic products to the US customers directly. Orchid redeems FCCBs aggregating to USD 25.69 million.
2011 Cephalosporin API manufacturing facility at Alathur was successfully re-inspected by
USFDA. Orchid received milestone payment from Merck on advancement of their research
initiative to discover, develop and commercialize molecules essential for the treatment of bacterial and fungal infections.
Orchid's API Manufacturing facility at Alathur was awarded with OHSAS 18000 : 2007 (Occupational Health and Safety Management System) certification.
Orchid's API Manufacturing facility at Alathur was re-assessed and was certified with ISO 9001 : 2008 (Quality Management System) and ISO 14001 : 2004 (Environmental Management System).
2012 Orchid Pharma successfully completed in Europe a Phase I trial of its orally administered
PDE4 (phosphodiesterase 4 inhibitor) molecule OCID 2987 positioned for the treatment of inflammatory disorders including COPD (Chronic Obstructive Pulmonary Disease).
Orchid successfully redeemed the outstanding FCCBs, including yield-to-maturity, aggregating to USD 167.64 million.
Orchid Pharma enters into agreement to transfer its Penicillin & Penem API business & its API facilities in Aurangabad to Hospira.
Corporate Governance
Our ApproachEver since our inception, we committed ourselves to the highest standards of corporate governance. We believe that a robust corporate governance policy drives healthy business growth and reinforces vibrant markets, besides serving an important instrument of investor protection. Governance also provides an appropriate framework for the Board and the Management to set corporate objectives to enhance shareholder value.
Core ValuesOur corporate governance is defined by clear, established values, standards of business conduct and code of ethics.
Business EthicsOur business code reaffirms our adherence to core values and serves as a practical guide to everyday work life. Constantly accommodating new legal and regulatory developments, this code is a valuable resource in assisting employees with decision making to ensure that business is conducted with integrity. This business code also helps in preventing, detecting, reporting and addressing any allegation of misconduct and violations of law.
TransparencyAdhering to the principle of fair disclosure, we regularly provide information on the company’s position and significant changes in business activities to all our stakeholders.
Safety Excellence
Safety FirstAt Orchid, safety is a part of the corporate culture. This includes infrastructural, employee, environmental and community safety. Starting with the employee induction programme, training programmes on various aspects of operational safety are periodically conducted. In association with a global expert on safety procedures, a number of initiatives have been designed to ensure that all manufacturing processes and systems are executed in the safest manner. These include:
Use of high-end technologies to recycle discharge and make it toxic free through a series of processes thereby leading to zero discharge manufacturing
Three-tier safety committees to monitor safety initiatives, standard operating procedures (SOPs), process and working standards for R&D and manufacturing units
Round-the-clock medical care and safety training for all employees Use of sophisticated equipment in mobile vans to monitor air quality inside and outside
plants
Safety visionTo become a world-class, safety-driven pharmaceutical organisation by conducting our business processes and operations with commitment to the highest standards of safety, health and environment.
Safety goalOur safety vision is inspired by a succinctly stated goal – 'Zero Incident'.
We believe the goal of a zero incident workplace is achievable by developing and maintaining management systems that allow us to control risk by ensuring engineering controls and administrative controls. Our ultimate goal is to have zero accidents, zero injuries and zero fatalities – leading to zero incidents.
Our Safety PrinciplesThe company formulated seven safety principles:
Safety is a core organisational value. Management is responsible for preventing injuries. All injuries can be prevented and occupational exposures minimised. All incidents must be reported and acted upon. Working safely is a condition of employment and contract. Training employees in safety is essential. Safety makes good business.
Tara – Our face of safetyAt Orchid, safety is a culture and has always been kept at the forefront. We treasure our employees and value our infrastructure thereby inculcating the highest levels of safety standards. Tara represents our movement for a safer world.
Tara was born as the outcome of our desire to have a symbol that reinforces our concern for
safe practices for a safer world. Tara, a young girl child reminds someone is waiting back home – an emotional imperative to consciously adhere to safe practices. She communicates a simple reality – that safety is important not just for us today, but for our future generations as well.
QualityWe accord the highest emphasis to quality and it is given as much attention as innovation and value creation. A fully computerised quality control system monitors operations round-the-clock thereby ensuring highest standards of quality.
CorporateAt Orchid, maintaining highest levels of quality helps us deliver excellence in everything we do reflecting not only in robust growth but also in personal development and enhanced management abilities.
ManufacturingOur manufacturing facilities deploy state-of-the-art technologies and automated facilities that ensure the highest levels of process integrity and product quality. Our facilities have fully self-reliant Quality Control departments with sophisticated equipment such as HPLCs, GCs, titrators, FTIRs and UV spectrometers to ensure conformance to stringent quality standards. Our sterile plants (for both crystallisation and lyophillisation) have been built with European equipment, fabrication and support systems. Our facilities have successfully gone through several inspections by the US FDA and UK MHRA among others, enabling a steady flow of product approvals. We have also established an end-to-end connected infrastructure for drug discovery and development in Chennai (India) to meet world-class standards with associated facilities for process research, pharma research and biotechnology.
ProductOur world-class quality products and facilities, regulatory and compliance systems conform to international standards. In fact, we have been the youngest pharmaceutical
company in India to receive the coveted ISO Certification.
Environment Sustainability
Sustainability is one of our core values, and integral to our overall vision in shaping a dream. As a responsible member of the society, we realise that we cannot alienate ourselves from the eco-system and we have to give back to the world what we take. We know we operate in a sector that can have a significant impact on the environment, which means we have an even greater responsibility to make sure we use resources wisely, and manage our waste and emissions effectively.
We have been awarded the coveted ISO 14001-Quality Certification for our Quality Environment Management Systems. Our facilities are the first and among the few 'zero discharge' pharmaceutical facilities in India.
We also have sophisticated technologies for vent gas condensation, solvent re-circulation and reverse osmosis. Significant resources have also been invested in putting up world-class effluent treatment infrastructure – regarded as a showcase in the Indian pharmaceutical industry. In addition, we also have a mobile vehicle equipped with state-of-the-art monitoring equipments to constantly measure the quality of ambient air in and around our manufacturing facilities.
Our green policies have earned us the reputation of being a pioneer in Environmental Management Systems and have won appreciation from various delegates including the Confederation of Indian Industry (CII). The Government of India and various industry apex associations have also awarded us the Gold standard in Environmental Safety and Protection.
Awards & AccoladesAwards and accolades have been an important part of the Orchid success story. Over the years, Orchid has received many awards and accolades in recognition of its pioneering achievements.
General Awards
Orchid Research Laboratories Limited (ORLL), the wholly-owned drug discovery subsidiary was conferred the Frost & Sullivan Award for Partner of Choice in Contract Research – Collaborative Drug Discovery in 2007.
Orchid was awarded the Employer-Employee Relation Award in the Large Scale Industry category by the Rotary Club of Madras South West in 2006.
Orchid was awarded the prestigious ‘Partner of Choice for Competitive Excellence’ Award by Frost & Sullivan in 2005.
In 2002 Orchid was awarded the MMA Award for Managerial Excellence in the Manufacturing sector by the then Governor of Tamil Nadu, Hon’ble Shri. PS Ramamohan Rao.
Performance / Quality Awards
Orchid was conferred with the Export Excellence Award 2010-11 by MEPZ – Special Economic Zone, Government of India.
Orchid received EXIM Achievement Award 2011 for its meritorious export performance under the category Air Exports by The Tamil Chamber of Commerce, Chennai.
Orchid was conferred the Gold Patent Award for the year 2010-11 in recognition of its commendable contribution to R&D in Drug Discovery Sector by the Pharmaceutical Export Promotion Council. The award was presented by Shri. N. Kiran Kumar Reddy, Hon’ble Chief Minister of Andhra Pradesh.
Orchid’s manufacturing facility located in Aurangabad (Maharashtra) was honoured with the Facility of the Year Award 2009 (Regional Excellence Category) by ISPE, Interphex and the Pharmaceutical Processing magazine.
Orchid was awarded the EXIM Achievement Award 2007-08 for its meritorious export performance by the Tamil Chamber of Commerce, Chennai.
In 2003, Orchid was awarded the Gold Award for Excellence and Business Prestige at the Quality Summit 2003, New York.
Orchid was awarded the trophy for Excellent Performance in Exports for 1998-99 from the then Prime Minister of India, Hon'ble Atal Behari Vajpayee held at Vigyan Bhavan, New Delhi.
Orchid received the Industrial Economist’s Business Excellence Award 1996-97 for meritorious performance.
Orchid has been consecutively awarded the CEU Export Award for its commendable export performance in 1994-95, 1995-96 and 1996-97.
Orchid was awarded the Trophy for meritorious performance in exports for the year 1995-96, by the Ministry of Commerce, Government of India and the award was given by the then President of India, Shri. Shankar Dayal Sharma.
Orchid was selected by The All India Manufacturers Organisation (Tamil Nadu State Board) for the Visvesvaraya Industrial Award for its performance during 1995-96.
CSR Awards
Orchid’s social responsibility initiatives were honoured by the Tamil Nadu Government with the Award for Corporate Social Responsibility for the year 2008-09.
Orchid was awarded the Environment & Community Service Award 2003-04 by the Rotary Club of Madras.
Orchid was adjudged as the Best Corporate Citizen for the year 2000 and was awarded the prestigious, "Mother Teresa Award", by the Loyola Institute of Business Administration in 2001.
Environment Awards
Orchid was awarded IGCW – 2011 Green Innovation Award for the outstanding research in the field of Green Chemistry & Engineering in 2011.
Orchid was conferred the Shrishti Good Green Governance (G3) Award in 2011. The award was presented by Mr. Salman Khurshid, Minister of Water Resources & Minority Affairs, Government of India.
In 2010, for "Outstanding Achievement in Environment Management in the Chemical sector", Orchid was conferred with the Silver Award by Greentech Foundation.
Orchid was awarded the "Siemens Ecovatives-IBN Live Award 2010" in recognition of our outstanding initiatives in Energy Management (Low Energy and Natural Resource Conservation).
In 2010, Orchid’s Alathur API facility received the Bureau of Energy Efficiency (BEE) Certificate of Merit on Energy Efficiency by the Ministry of Power, Government of India.
Orchid’s endeavour in the area of energy conservation was recognised with the “Excellent Energy Efficient Unit” in the 9th Energy Efficiency Summit 2010 organised by the CII (Confederation of Indian Industries). This award was recently presented by Mr.Ajay Mathur, Director General of Bureau of Energy Efficiency, Ministry of Power, and Government of India.
Orchid’s Aurangabad facility received the Dr.R J Rathi Award for Environment Pollution & Control in industries in Maharashtra for the year 2010 (constituted by Maharashtra Chamber of Commerce Industries & Agriculture, Pune).
Orchid’s endeavor in the area of Environmental Excellence was recognised with the TERI Corporate Award for Environmental Excellence 2009. The award was presented by the Hon’ble President of India, Smt. Pratibha Devisingh Patil.
In 2008, Orchid’s Alathur Unit was conferred with the National Energy Conservation Award 2008 (Drugs & Pharmaceuticals sector) by the Ministry of Power, Government of India.
Orchid was awarded the Good Green Governance Award 2007 in the Manufacturing (non-metallurgical) category by the Srishti Group of Publications.
Orchid’s world-class Environment Management Systems were conferred with yet another accolade in 2003, i.e., MS Swaminathan Award for Environment Management.
In 2003, Orchid’s remarkable achievements in the area of environment protection were recognized with the 'Golden Peacock Award'.
Orchid’s Alathur facility was awarded the prestigious Excellent Energy Efficient Unit award, a National Award for Excellence in Energy Management by the CII in 2002 as well as in 2001.
Orchid was nominated among India’s Greenest Companies listing by the Business Today magazine in 2001.
Safety Awards
In 2011, Orchid received the "Green Tech Gold Safety Award" by Greentech Foundation. The award was presented by Dr RK Srivastav, Director General of Health Services, Ministry of Health & Family Welfare, Gov of India and Mr Kamaleshwar Sharan, President, Greentech Foundation.
Orchid’s Alathur facility received the Greentech Safety Award 2010 (Silver award) in pharmaceutical sector for outstanding achievement in Safety Management given by Greentech Foundation.
Orchid was awarded the "Certificate of Merit Award" for 2010 by the CII for Excellence in Environment, Health and Safety.
Orchid was awarded the Certificate of Merit for Excellence in Management of Safety, Health & Environment (SHE) for the year 2008 by the Indian Chemical Council (ICC).
Orchid has been awarded the “Leadership & Excellence Award in Safety, Health, and Environment & Manufacturing” by the CII in 2002.
Orchid Trust
Placing community before commerceAs a global pharmaceutical corporation, our desire to cure extends beyond health care, spilling over to ills in the social and economic arenas. This sensitivity to the community related issues has spurred us into creating a development trust, which has embarked on a variety of projects, aimed at the socially and economically deprived sections.
Our MissionTo accelerate sustainable development of rural areas by empowering socially and economically deprived sections.
Orchid's Tripartite Approach
Our community development agenda is derived from the belief that community benefits grow when industry, government and institutions work collaboratively.
Government: It has the mechanics to receive and document the needs of society. It also has the legislative and administrative power to take forward development programs.
Industry: It has the strength of technology and managerial skills required to identify solutions and execute projects in a time-bound manner.
NGOs and other Institutions: They penetrate deep into the community to propagate ideas and act as a vibrant feedback mechanism.
We have always believed that enhancing the social well-being of individuals would add a lot more meaning to our overall business existence. Caring for the people and the
community has therefore been an important facet of our business philosophy. We are happy that we have influenced the lives of several people in the vicinity of our facilitates through the several initiatives and programmes undertaken by the Trust.
All donations/contributions to The Orchid Trust are exempt from Income Tax under section 80G.
For more information on our corporate responsibility efforts and to collaborate with us, kindly contact:
The Project Co-ordinatorOrchid Trust2nd Floor, 'Crown Court'#128, Cathedral RoadChennai 600 086, IndiaPh: +91 - 44 - 2811 0914Email: [email protected]
Focus Areas
Orchid Trust's key thrust areas Education Health Self Employment Capacity Building Community Asset Development
InitiativesThe Trust has adopted 24 villages and 6 panchayats and work continuously in implementing several welfare schemes in key-identified thrust areas like education, health, self-employment, capacity building, community asset development and youth development etc.
Education - Lighting the LifeOne tree can make a million matches and one match can destroy a million trees. Orchid Trust believes in building up society with a strong educational base embedded with noble humanistic values. Hence, it aims at facilitation and educational endeavours of the children making them generators like trees. Orchid Trust has thus initiated and continues to implement several activities that aim at improving the educational inputs in the neighbourhoods, especially those that target children from poor households.
Healthcare - Step towards creation of Healthy FamilyTo promote health awareness and to provide medical facilities to the needy especially to those who are devoid of health facilities either due to financial crunch or due to being in far flung areas. Orchid Trust has consistently focused on health issues in the neighbourhood. Orchid fills the gap and proactively helps to meet the “unmet health needs” of the community.
Youth Empowerment - Moulding the Future.Youth spearheads the direction of the society. Hence, adequate support and opportunities need to be provided to tap their potential appropriately. Problems such as unemployment, drug addiction, alcoholism, frustration, anger that plague the society today needs to be addressed in a timely manner. Orchid Trust has evolved strategies to prepare the unemployed rural youth to succeed in realising their dreams and contribute back to the society.
Women Empowerment - Towards sustainable growthOrchid Trust’s intervention in women’s development stems from the understanding that women are the primary agents of family and community development. Women invest all their income in their families. Hence it is important that they have access to and control over income. Orchid Trust initiatives in this sector are geared towards this. Orchid Trust organises regular group meetings to understand the SHGs (Self Help Groups) as well as to motivate them to function optimally. We have adopted 140 women self help groups having more than 1800 SHG members in 25 villages to improve their economic condition through income generation programmes.
Community Asset Creation - Enhancing the quality of LifeWe have embarked on a number of initiatives in supplementing the existing village infrastructure with additional assets. Significant money has been invested in the area of community asset creation by evoking public participation. Infrastructure like school buildings, community halls, tuition centres, primary health centres, streetlights, drinking water wells, water coolers etc. have been provided by the Trust.
Employee InvolvementOur strong belief in community involvement encourages our people to take part in local projects. This helps in developing valuable skills.
Product profile
Cardiovascular
Brand Name Generic Name
ESAMLO - AT 10'S S (-) Amlodipine Besilate and Atenolol Tablets
ESAMLO 2.5 10'S S (-) Amlodipine Besilate Tablets
ESAMLO 5 10'S S (-) Amlodipine Besilate Tablets
INDAP 2.5 10'S Indapamide tablets USP
INDAP AT 10'S Indapamide with Atenolol tablets
INDAP SR 1.5 10'S Indapamide sustained release tablets
LOSAVAS 25 10'S Losartan potassium tablets
LOSAVAS 50 10'S Losartan potassium tablets
LOSAVAS H 50 10'S Losartan potassium with hydrochlorothiazide tablets
METO AM 25 10S Metoprolol ER with Amlodipine Tablets
METO AM 50 10S Metoprolol ER with Amlodipine Tablets
METO ER 100 10'S Metorolol Succinate Extended Release tablets USP
METO ER 12.5 10S Metorolol Succinate Extended Release tablets USP
METO ER 25 10'S Metorolol Succinate Extended Release tablets USP
METO ER 50 10'S Metorolol Succinate Extended Release tablets USP
METO ER HT 25 10S Metoprolol ER with Hydrochlorothiazide Tablets
METO ER HT 50 10S Metoprolol ER with Hydrochlorothiazide Tablets
OLSAVAS 20 10S Olmesartan Medoxomil Tablets
OLSAVAS 3 10S Olmesartan medoxomil, Hydrochlorothiazide and amlodipine tablets
OLSAVAS 40 10S Olmesartan Medoxomil Tablets
OLSAVAS AM 10S Olmesartan Medoxomil and Amlodipine tablets
OLSAVAS H 20 10S Olmesartan Medoxomil and Hydrochlorothiazide tablets
OLSAVAS H 40 10S Olmesartan Medoxomil and Hydrochlorothiazide tablets
LOL SR 40 10S Propranolol HCl sustained release capsules USP
LOL SR 80 10'S Propranolol HCl sustained release capsules USP
MANOPROLOL 10 10'S Propranolol Tablets IP
MANOPROLOL 20 10'S Propranolol Tablets IP
MANOPROLOL 40 10'S Propranolol Tablets IP
AMLO - AT 10'S Amlodipine Besilate and Atenolol Tablets
AMLO - L 10'S Amlodipine Besilate and Lisinopril Tablets
AMLO 10 10'S Amlodipine tablets IP
AMLO 2.5 10'S Amlodipine tablets IP
AMLO 5 10'S Amlodipine tablets IP
HENLETOR 10 10S Torsemide Tablets
HENLETOR 20 10S Torsemide Tablets
HENLETOR 5 10S Torsemide Tablets
MANOTEN 25 14'S Altenolol Tablets IP
MANOTEN 50 14'S Altenolol Tablets IP
NEBIRING 2.5 10S Nebivolol Tablets IP
NEBIRING 5 10S Nebivolol Tablets IP
R.PRIL 1.25 10'S Ramipril capsules
R.PRIL 2.5 10'S Ramipril capsules
R.PRIL 5 10'S Ramipril capsules
R.PRIL-H 10S Ramipril and Hydrochlorothiazide Tablets
TELMIVAS 20 10S Telmisartan Tablets
TELMIVAS 40 10S Telmisartan Tablets
TELMIVAS 80 10S Telmisartan Tablets
TELMIVAS H 10S Telmisartan and Hydrochlorothiazide Tablets
TELMIVAS AM 10S Telmisartan and Amlodipine Tablets
TAZ 20 SYN 10S Trimetazidine HCl tablets
TAZ SR 60 10'S Trimetazidine HCl tablets
PIDLET 75 10'S Clopidogrel Tablets USP
PIDLET EQ 10S Clopidogrel and Asprin Tablets
PIDLET PLUS 10'S Clopidogrel and Asprin Tablets
ZARIFA (5MG/100ML) Tirofiban 5 mg
PLEOSTIN 10 10S Atorvastatin tablets
PLEOSTIN 20 10S Atorvastatin tablets
PLEOSTIN 5 10S Atorvastatin tablets
PLEOSTIN F 10 7S Atorvastatin and Fenofibrate Tablets
PLEOSTIN F 5 7S Atorvastatin and Fenofibrate Tablets
PLEOSTIN-EZ 10 10S Atrovastatin and Ezetimibe tablets
FIBROFEN 10S Fenofibrate tablets
ROLIP 10MG TAB 10S Rosuvastatin Tablets IP
ROLIP 20MG TAB 10S Rosuvastatin Tablets IP
ROLIP 5MG TAB 10S Rosuvastatin Tablets IP
Anti-Diabetic
Brand Name Generic Name
G.REG 10'S Metformin HCL tablets IP
G.REG SR 1000 10'S Metformin HCl sustained release tablets
G.REG SR 500 10'S Metformin HCl sustained release tablets
GLIMTIDE 1 10'S Glimipride Tablets
GLIMTIDE 2 10'S Glimipride Tablets
GLIMTIDE 4 10'S Glimipride Tablets
GLIMTIDE FORTE 10'S Glimepiride and Metformin ( extented release )Tablets
GLIMTIDE PLUS 10'S Glimepiride and Metformin ( extented release )Tablets
PIOCON 15 10'S Pioglitazone Tablets
PIOCON 30 10'S Pioglitazone Tablets
PIOCON FORTE 10S Pioglitazone with Metformin Tablets
PIOCON PLUS 10S Pioglitazone with Metformin Tablets
VOBIS 0.2 10S Voglibose tablets
VOBIS 0.3 10S Voglibose tablets
VOBIS M 0.2 10S Voglibose and Metformin HCl (Sustained release)tablets
VOBIS M-0.3 Voglibose and Metformin HCl (Sustained release)tablets
ACARB 25 10'S Acarbose tablets IP
ACARB 50 10'S Acarbose tablets IP
BENFORMIN - LS 10'S Metformin HCL and Glibenclamide Tablets
BENFORMIN 10'S Metformin HCL and Glibenclamide Tablets
BENFORMIN-HS 10'S Metformin HCL and Glibenclamide Tablets
CLAFORMIN - HS 10'S Metformin HCL and Gliclazide Tablets
CLAFORMIN 10'S Metformin HCL and Gliclazide Tablets
GLICLA 40 10'S Gliclazide Tablets BP
GLICLA 80 10'S Gliclazide Tablets BP
PAGE 0.5 10'S Repaglinide tablets USP
PAGE 1 10'S Repaglinide tablets USP
PIOCON GM 1 10S Glimepride, Pioglitazone and Metformin (ER) Tablets
PIOCON GM 2 10S Glimepride, Pioglitazone and Metformin (ER) Tablets
Neuropsychiatry
Brand Name Generic Name
ALZEPIL 10 10S Donepezil Hydrochloride tablet IP
ALZEPIL 5 10S Donepezil Hydrochloride tablet IP
2-DEP-20 Duloxetin Tablets
2-DEP-30 Duloxetin Tablets
AMICHLOR - DS 10'S Amitriptyline and Chlordiazepoxide Tablets USP
AMICHLOR 10'S Amitriptyline and Chlordiazepoxide Tablets USP
AMIT 10 10'S Amitriptyline Tablets IP
AMIT 25 10'S Amitriptyline Tablets IP
AMIT 50 10'S Amitriptyline Tablets IP
AMIT 75 10'S Amitriptyline Tablets IP
DOTH 100 10'S Dothiepin HCl Tablets BP
DOTH 25 10'S Dothiepin HCl Tablets BP
DOTH 50 10'S Dothiepin HCl Tablets BP
DOTH 75 10'S Dothiepin HCl Tablets BP
FLUTHIXOLE 10S Flupentixol and Melitracen Tablets
LINDEP 100 10'S Sertraline tablets
LINDEP 50 10'S Sertraline tablets
NOC 10 10'S Fluoxetine capsules USP
NOC 20 10'S Fluoxetine capsules USP
SALIDEP 40 10'S Fluoxetine capsules USP
TOPDEP 10 10'S Citalopram hydrobromide tablets
TOPDEP S 10 10'S Escitalopram tablets
TOPDEP S 20 10'S Escitalopram tablets
BIOCOBAL P75 10S Pregabalin and Mecobalamin capsules
BIOGABA 10S Gabapentin Mecobalamin and Alpha Lipoic Acid Tablets
PNA 100 10'S Phenytoin sodium tablets IP E
PNA 200 10'S Phenytoin sodium tablets IP
RISCALM - LS 10'S Risperidone and Trihexyphenidyl HCl Tablets
TOPSULANT 100 10S Topiramate Tablets
TOPSULANT 25 10S Topiramate Tablets
TOPSULANT 50 10S Topiramate Tablets
VALP ER 250 10'S Divalproex sodium ER Tablets
VALP ER 500 10S Divalproex sodium ER Tablets
ZAC 10 10'S Clobazam tablets
ZAC 5 10'S Clobazam tablets
FLUGRAINE 10 10'S Flunarizine Tablets
FLUGRAINE 5 10'S Flunarizine Tablets
DINE 2.5 10'S Procyclidine HCl tablets IP
DINE 5 10'S Procyclidine HCl tablets IP
MANOHEXY 10'S Trihexyphenydil HCl Tablets
MANOHEXY 5 10'S Trihexyphenydil HCl Tablets
AMISELECT 100 10S Amisulpride Tablets
AMISELECT 200 10S Amisulpride Tablets
AMISELECT 50 10S Amisulpride Tablets
CHROZAP 100 10'S Clozapine tablets USP
CHROZAP 50 10'S Clozapine tablets USP
MANOCALM FORTE 10'S
Trifluoperazine HCl,Trihexyphenidyl and Chloropromazine HCl Tablets
MANOCALM PLUS 10'S
Trihexyphenydil HCl and Trifluoperazine Tablets
MANODOL 1.5 KIT 4'S
Haloperidol and Trihexyphenidyl Tablets
MANODOL 5 KIT 4'S Haloperidol and Trihexyphenidyl Tablets
MANZA 10 10'S Olanzapine tablets
MANZA 15 10'S Olanzapine tablets
MANZA 20 10'S Olanzapine tablets
MANZA 5 10'S Olanzapine tablets
RISCALM 1 10'S Risperidone tablets
RISCALM 2 10'S Risperidone tablets
RISCALM 3 10'S Risperidone tablets
RISCALM 4 10'S Risperidone tablets
RISCALM FORTE 10'S Risperidone and Trihexyphenidyl HCl Tablets
RISCALM PLUS 10'S Risperidone and Trihexyphenidyl HCl Tablets
GOVERT 16 10S Betahistine dihydrochloride dispersible tablets
GOVERT 24 10S Betahistine dihydrochloride dispersible tablets
GOVERT 8 10S Betahistine dihydrochloride dispersible tablets
L.PAM 1 10'S Lorazepam Tablets BP
L.PAM 2 10'S Lorazepam Tablets BP
L.PAM 3 10'S Lorazepam Tablets BP
LORA INJ 2ML Lorazepam Tablets BP
MANOREST 0.25 10'S Alprazolam Tablets IP
MANOREST 0.5 10'S Alprazolam Tablets IP
MANOREST 1 10'S Alprazolam Tablets IP
ZEE 0.5 10'S Clonazepam Tablets USP
ZEE 1 10'S Clonazepam Tablets USP
ZEE 2 10'S Clonazepam Tablets USP
CITIBRAL 10S Citicoline Tablets
CITIBRAL 5S INJ Citicoline Injection
IDEOX 10S Idebenone tablets
PIRAC 400 10'S Piracetam capsules
PIRAC INJ 15ML Piracetam Injection
DISULFIRAM 250 10'S Disulfiram Tablets IP
RESENZ 75 10S Pregabalin capsules
Nutritional Supplements
Brand Name Generic Name
CALPIDA 10S Calcium Orolate tablets
DIACOBAL - S 10'S Mecobalamin Tablets
DIACOBAL 1.5MG 10'S Mecobalamin Tablets
DIACOBAL PLUS 1 10S Pyridoxine HCl, Mecobalamin and Nicotinamide tablets
DIACOBAL PLUS 1 INJ Methylcobalamin, Pyridoxine HCl and Niacinamide injection Pack 2 ml
DIACOBAL SYRUP 1 200ML
PyridoxineHCl,Mecobalamin and Lysine HCl syrup
DIACOBAL VIT 1 INJ Vitamin C IP, Mecobalamin, folic acid and Niacinamide injection
OXIBET (DIETARY) 10S Anti-Oxidants, Vitamins and Minerals Capsules
VITAMIN C INJ Vitamin C injection IP
BENFAGE FORTE 10S Pyridoxine HCl, Mecobalamin, Benfothiamine, Inositol and Alpha lipoic acid capsules
BENFAGE PLUS 10S Pyridoxine HCl ,Mecobalamin,Benfothiamine, and folic acid tablets
BENFO PLUS 10S Pyridoxine HCl, Mecobalamin,Benfothiamine, and folic acid tablets
BIOCOBAL 1.5MG 10'S Mecobalamin Tablets
BIOCOBAL 500 MCG 10'S Mecobalamin Tablets
BIOCOBAL 500MCG INJ 5S
Methylcobalamin injection
BIOCOBAL FORTE 1 10S Mecobalamin and Vitamin tablets
BIOCOBAL FORTE 1 INJ Methylcobalamin, Pyridoxine HCl and Niacinamide injection Pack 2 ml
BIOCOBAL PLUS 1 10S Pyridoxine HCl, Mecobalamin and Nicotinamide tablets
BIOCOBAL PLUS 1 INJ Methylcobalamin, Pyridoxine HCl and Niacinamide injection Pack 2 ml
BIOCOBAL SYRUP 1 200ML
PyridoxineHCl,Mecobalamin and Lysine HCl syrup
BIOCOBAL-5 10S TAB Mecobalamin Tablets
GGG 24 10'S Ginkobiloba 60mg, Ginseng 42.5mg, Garlic 2mg Softgels
BENFO FORTE 10S Pyridoxine HCl, Mecobalamin, Benfothiamine, Inositol and Alpha lipoic acid capsules
DIACOBAL 500 MCG 10'S Mecobalamin tablets
DIACOBAL 500 MCG INJ 1 ML 5S
Methylcobalamin injection
DIACOBAL FORTE 1 10S Mecobalamin and Vitamin tablets
DIACOBAL FORTE 1 INJ Methylcobalamin, Pyridoxine HCl and Niacinamide injection Pack 2 ml
LYCOTOM-1 Lycopene, Selenium and Vitamin E Capsules
VITMINAC (DIETARY) 10S
Acetylcysteine, Vit. C, E and A with Selenium, Chromium Capsules
SURPARIN 40MG INJ Enoxaparin 40 mg
SURPARIN 60MG INJ Enoxaparin 60 mg
Others
Brand Name Generic Name
XENOCET 10S Levocetirizine Tablets IP
CEFACURE 100 DROPS Cephalexin
CEFACURE 250MG 10S DT - OCPL
Cephalexin Dispersible Tablets
CEFACURE 500MG CAPS 10S - OCPL
Cephalexin Dispersible Tablets
CEPOTIL 100MG 4S TABS - OCPL
Cefpodoxime Proxetil Tablets USP
CEPOTIL 200MG 4S TABS - OCPL
Cefpodoxime Proxetil Tablets USP
SPIZEF 250MG TABS 4S - OCPL
Cefuroxime Axetil Tablets USP
SPIZEF 500MG TABS 4S - OCPL
Cefuroxime Axetil Tablets USP
ORNIWELL 10S Ofloxacin & Ornidazole Tablets
VOCOZO 200mg Voriconazole
VOCOZO 200mg Inj Voriconazole
PODOBID 200MG TABS 10S Cefpodoxime Proxetil Tablets USP
PODOBID 50 DRY SYRUP Cefpodoxime Proxetil Oral Suspension IP
PODOBID DT 100MG TABS 10S
Cefpodoxime Proxetil Tablets USP
PODOBID DT 50MG TABS 10S
Cefpodoxime Proxetil Tablets USP
ZAFIL 50 DRY SYRUP Cefixime Oral Suspension IP
ZAFIL DT-100 10S Cefixime Dispersible Tablets
ZAFIL-200 10S Cefixime Tablets IP
EVERCEF 250 4'S Cefuroxime Axetil Tablets USP
EVERCEF 500 4'S Cefuroxime Axetil Tablets USP
MACROAZI 250 6S Azithromycin Tablets IP
MACROAZI 500 3S Azithromycin Tablets IP
ORFIX 200 10S TAB Cefixime Dispersible Tablets
ORFIX CV 10S Cefixime and Clavulanate Potassium Tablets
ORFIX DT 100MG 10S - OCPL Cefixime Dispersible Tablets
ORFIX-DT 50MG TAB 10S Cefixime Dispersible Tablets
ORFIX-O 100 DT 10S Cefixime and Ofloxacin Dispersible Tablets
ORFIX-O TAB 10S Cefixime and Ofloxacin Tablets
CEBANEX 1G Cefoperazone 500 mg + Sulbactum 500 mg
CEBANEX 2G Cefoperazone1g + Sulbactum1g
CEBANEX FORTE 1.5G Cefoperazone 1g + Sulbactam 0.5g
CEBANEX FORTE 3.0G Cefoperazone 2g + Sulbactam 1g
CEFOGRAM 1 G Ceftriaxone 1 g
CEFOGRAM 250 MG Ceftriaxone 250 mg
CEFOGRAM 500 MG Ceftriaxone 500 mg
CEFOGRAM TZB 1 G Ceftriaxone 1000 mg + Tazobactam 125 mg
CEPIROM 1 G Cefpirome 1g
CRITIG 50MG INJ Tigecycline
DUOPIME 1 G Cefepime 1g + Tazobactam 125 mg
DOROR 500MG INJ. Doripenem
MEROMER 0.5 G Meropenem 0.5 g
MEROMER 1G Meropenem 1g
MEROMER 250 MG Meropenem 250 mg
ORCHIDOL INJ 1 ML Tramadol 1 ml
ORCHIDOL INJ 2 ML Tramadol 2 ml
ORCHIDOL TAB 50MG Tramadol 50 mg
ORKACIN 100 MG Amikacin 100 mg
ORKACIN 250 MG Amikacin 250 mg
ORKACIN 500 MG Amikacin 500 mg
ORLINA 600MG Linezolid 600 mg
ORPIME 1G Cefepime Hydrochloride 1g
ORZID 1G Ceftazidime 1g
ORZID 250MG Ceftazidime 250 mg
ORZID 2G Ceftazidime 2g
SEAZOX-250 MG Cefuroxime Axetil 250 mg
SEAZOX-500 MG Cefuroxime Axetil 500 mg
SPIZEF INJ 1.5 G Cefuroxime Sodium 1.5 g
SPIZEF INJ 750 MG Cefuroxime Sodium 750 mg
TAKEO 400 MG Teicoplanin 400 mg
TAX-O-BID 1G Cefotaxime Sodium 1 g
TAX-O-BID 250 MG Cefotaxime Sodium 250 mg
TAX-O-BID 500 MG Cefotaxime Sodium 500 mg
TAXTAM 1.5 G Cefotaxime 1 g + Sulbactum 500 mg
VYOPEM 200 MG Feropenem Sodium 200 mg
ZILONEM 500 MG Imipenem 500mg + Cilastatin 500 mg
ZOPERCIN 2.25 G Piperacillin 2g & Tazobactam 0.25 gm
ZOPERCIN 4.5 G Piperacillin 4g & Tazobactam 0.5 gm
THERMGO 120 SUSPENSION Paracetamol Suspension USP
THERMGO 250 SUSPENSION Paracetamol Suspension USP
THERMGO DROPS Acetaminophen Oral Suspension USP
THERMGO DT 250 10S Paracetamol Tablets IP
THERMGO-650 10S Paracetamol Tablets IP
THERMGO DT 250 10S Paracetamol Tablets IP
ELPIZOLE-20 10S Rabeprazole tablets IP
ELPIZOLE-D 10S Rabeprazole (EC) and Domperidone (SR) capsules
MANEZ 20 10S Pantoprazole tablets
MANEZ 40 10S Pantoprazole tablets
MOBIUM 10'S Calcium dobesilate monohydrate capsules
XENORAB-DSR 10S Rabeprazole and Domperidone SR Capsules
XENOCOF A 100ML Terbutaline Sulphate, Bromhexine HCl, Guaiphenesin with Menthol
XENOCOF D 100ML Chlorpheniramine maleate, codeine phosphate and menthol syrup
XENOCOF 100ML Ambroxol, Guaiphenesin, Phenylephrine, Chlorpheniramine maleate with menthol
GEROLAC 100ML Lactulose solution USP
DISMIS MM KIT Kit tablets of Mifepristone and Misoprostol
ETOSWIFT 400 10S Etodolac tablet USP
ETOSWIFT ER 400 10S Etodolac extended release tablet USP
ETOSWIFT ER 500 10S Etodolac extended release tablet USP
ORCHICAM 8 10S Lornoxicam Tablets
XENODOL 10S Aceclofenac and Paracetamol tablets
XENODOL-SP TAB 10S Aceclofenac,paracetamol,and serratiopeptidase tablets
VOCIFENAC 10S Aceclofenac and Thiocolchicoside tablets
DisclaimerProduct exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute as an offer for sales in territories where it is not permitted by law.
API (Active Pharmaceutical Products)
Cephalosporins - Orals
Product Pharmacopeia DMF Availability COS
Cefalexin EP / BP / USP / JP √ √
Cefadroxil EP / BP / USP / JP √ √
Cefixime EP / BP / USP √ √
Cefradine USP / EP / BP √ √
Cefuroxime Axetil (Amorphous) USP / EP / BP / JP √ √
Cefuroxime Axetil (Crystalline) USP √ -
Cefprozil USP √ -
Cefditoren Pivoxil (Amorphous) In-house √ -
Cefditoren Pivoxil (Crystalline) USP / JP √ -
Cefdinir USP / JP √ -
Cefpodoxime Proxetil USP / EP / JP √ -
Ceftibuten In-house √ -
Cefcapene Pivoxil Hydrochloride JP TIP -
Ceftamet Pivoxil JP TIP -
Cephalosporins - Injectibles
Product Pharmacopeia DMF availability
COS
Cefotaxime Sodium (Sterile) USP / EP/BP/JP √ √
Ceftriaxone Sodium (Sterile) USP / EP √ √
Ceftazidime Pentahydrate with Sodium Carbonate for Injection
USP / EP/BP/JP √ √
Cefazolin Sodium (Sterile) USP / EP/BP/JP √ √
Cefoxitin Sodium (Sterile) USP / EP/BP √ √
Cefepime + Arginine (Sterile) USP √ -
Cefpirome Sulphate In-house √ -
Cefuroxime Sodium (Sterile) USP / EP √ √
Ceforanide + L-Lysine USP √ -
Cefalothin Sodium Buffered (Sterile) EP √ -
Ceftizoxime Sodium (Sterile) USP √ -
Cefoperazone Sodium (Sterile) JP / EP TIP -
Cefotiam Hexetil JP TIP -
Cefotiam Hydrochloride JP TIP -
Cefozopran Hydrochloride JP TIP -
Veterinary Products
Product Pharmacopeia DMF availability COS
Cefalonium BP √ -
Cefquinome Sulphate (Sterile) In-house √ -
Ceftiofur Hydrochloride USP √ -
Ceftiofur Sodium (Sterile) In-house √ -
Carbapenems
Product Pharmacopeia DMF availability COS
Meropenem USP / JP √ -
Imipenem + Cilastatin USP / EP/BP/JP √ -
Doripenem In-house √ -
Biapenem In-house TIP -
Non-Antibiotics
Product Pharmacopeia DMF availability COS
Aripiprazole In-house √ -
Armodafinil In-house √ -
Dexlansoprazole In-house √ -
Duloxetine Hydrochloride In-house √ -
Eszopiclone In-house √ -
Felodipine USP / EP/BP √ -
Granisetron Hydrochloride EP/BP √ √
Ibandronate Sodium In-house √ -
Levetiracetam USP/EP √ -
Memantine Hydrochloride In-house √ -
Modafinil USP / EP √ √
Naratriptan Hydrochloride USP √ -
Nisoldipine In-house √ -
Paliperidone JP √ -
Phenytoin Sodium USP/EP/BP √ -
Pramipexole Dihydrochloride EP √ -
Quetiapine Fumarate USP/EP √ -
Rabeprazole Sodium In-house √ -
Rasagiline Mesylate In-house √ -
Rivastigmine Tartrate In-house √ -
Ropinirole Hydrochloride In-house √ -
Sumatriptan Succinate USP /EP/BP √ √
Tadalafil In-house √ -
Telmisartan USP / EP √ -
Terbinafine Hydrochloride USP / EP/BP √ √
Tolterodine Tartrate In-house √ -
Zaleplon USP √ -
Zolmitriptan In-house √ -
Penicillins
Product
Ampicillin+Sulbactum
Piperacilin+Tazobactum
DisclaimerProduct exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute as an offer for sales in territories where it is not permitted by law.
Active Pharmaceutical Ingredients
Alathur, Chennai – Antibiotic (Cephalosporin) APIOur API manufacturing plant located at Alathur, south of Chennai is one of the largest integrated antibiotic manufacturing complexes in India and specialises in the manufacture of cephalosporin active pharmaceutical ingredients (APIs). Set in a large industrial estate, the complex is a massive, state-of-the-art, most modern manufacturing complex that produces a wide range of cephalosporin bulk activities spread across different generations of cephalosporin bulk actives. Its world-class crystallisation and lyophillisation facilities have not only provided a global competitive edge, but have also helped achieve manufacturing excellence and differentiation.
With a capability to handle highly complex and hazardous reactions with utmost safety and efficiency, the plant’s operations are backed by a full spectrum of utilities including a captive power generation plant, high technology solvent recovery facilities, sophisticated quality control equipment and a 'zero-discharge' environment friendly effluent treatment plant. Our
manufacturing complex has been successfully audited and approved time and again by leading global regulatory agencies like the US FDA, UK MHRA, GMP, EDQM, TGA (Australian), Danish Medicines Agency, in addition to several quality, environment and safety management recognition.
INFRASTRUCTURE
Aurangabad, Maharastra - Antibiotic (Penicillin and Carbapenems) and Non-antibiotic APIOur API manufacturing complex in Aurangabad, near Mumbai provides multi-therapeutic product offerings comprising high-end betalactams, carbapenems and non-penicillin, non-cephalosporin (NPNC) APIs. Spread across a large expanse, this facility is a world-class API manufacturing complex which can handle complex synthesis and reactions with the highest levels of safety and productivity.
This infrastructure uses complex gases and a high technology hydrogenator system. World-class utilities, solvent recovery systems and quality control infrastructure support the operations.
This manufacturing complex has also received global accolades for its environment, operational efficiency and safety management systems. The facility has also been approved by leading regulatory agencies.
Formulations
Irungattukottai, Chennai - Oral Formulations (Generics)Our modern oral formulations manufacturing facility at Irungattukottai (IKKT), near Chennai has modern infrastructure geared to offer high throughput. Coupled with world-class R&D labs, this formulations infrastructure is in the forefront of our successful entry into the advanced markets of US and Europe. With a vast site area, our oral formulations facility manufactures various types of dosage forms such as oral tablets and capsules in diverse dosage strengths and product categories.
The facility has been inspected and approved by leading regulatory agencies including the US FDA, UK MHRA, MCC (South Africa) and Danish Medicines Agency, based on specific filings.
Several ANDAs (abbreviated new drug applications) have been filed from this complex with approvals and new launches underway.
The formulations facility also houses a modern R&D centre for pharmaceuticals research.
Alathur, Chennai - Oral Formulations (Emerging)Oral non-cephalosporin formulations facilityOur oral non-cephalosporin formulations facility specialises in the manufacturing of nutraceutical products. The facility produces a range of dietary supplements for the advanced markets. Many other high-value products like anti-diabetics, cardio vascular drugs (CVS), anti-depressants and anti-epileptics are manufactured in this facility to cater to the emerging markets.
Built to GMP (good manufacturing practices) standards (WHO guidelines), this facility has state-of-the-art packaging machinery and a full-spectrum, dedicated quality control and microbiological services, adding distinctiveness to the manufacturing quality. Designed for optimal operating conditions and uni-directional flow of resources and materials, the facility has been approved by the Australian-TGA and is being offered for inspection by several other leading international regulatory agencies.
Oral cephalosporin formulations facilityOur oral cephalosporin formulations facility manufactures cephalosporin oral products dedicated to the domestic and emerging markets. The facility has the capability to manufacture different dosage forms like tablets, capsules, dry syrups and liquid orals. The facility conforms to cGMP standards and is approved by the WHO.
R&DApart from providing quality and affordable generic drugs to the global healthcare system, focus on R&D is a key value driver at Orchid. We recognise the importance of developing knowledge-intensive businesses as drivers of future growth. Orchid is a partner of choice to select global pharma companies in the areas of new chemical entity (NCE) development, novel drug delivery systems (NDDS) development, custom synthesis and R&D services. Our R&D Centres located in Chennai are GLP (Good Laboratory Practice) certified and equipped with sophisticated analytical and chemical laboratory equipment, supported by a good technical infrastructure for discovering and developing new drugs.
Our scientific personnel comprise of over 600 scientists across the entire spectrum of R&D and analytical research, working in various areas of drug discovery and development in addition to CMC (chemistry, manufacturing and controls), pharma research and other related processes and pharma research activities. Our people strive to create clinically differentiated drugs and diagnostics to help people live longer and healthier. To drive a stronger focus in the discovery and development area, we have developed a proprietary product pipeline and collaborated with multinational companies for discovery of new chemical entities to undertake co-discovery and/or co-development projects, as well as provide custom research services.
R&D InfrastructureOur core competence has always been in state-of-the-art development and manufacturing infrastructure. We have four R&D divisions dedicated to process research, drug discovery and development, pharmaceutical research and biotechnology. These research facilities are in the vanguard of creating generic product pipelines, proprietary discovery pipelines, novel processes and formulations, each aimed at building valuable intellectual property. From modeling of a new drug candidate in silico to its validation in an animal model, we are capable of conducting all research activities in-house. Sophisticated equipment and modern bioinformatics provide an edge to Orchid's drug discovery activities. The National Good Laboratory Practices (GLP) Monitoring Authority of India, aligned to OECD Principles of GLP has also certified our R&D facilities for GLP compliance.
Our end-to-end connected infrastructure, which enables complete value-chain integration, remains a key driver of our growth in the diverse and differentiated arenas of generic and discovery research, encompassing the entire pharmaceutical spectrum.
CapabilitiesWe are fully capable of meeting challenges of modern-day drug discovery, given our infrastructure and the competencies for innovative medicinal chemistry and biology as well as the deployment of sharper efficacy and safety screens. We have one of the most comprehensive research programs in the Indian pharmaceutical field. Spread across two campuses of 12 acres in Chennai, the research initiatives are divisionalised into core areas. Together, these streams signify the generation of vital intellectual property.
Research
Process ResearchOur process research team is focused on developing patentable non-infringing processes for the company's operations in the regulated markets.
Pharma ResearchThe pharma research division covers both the antibiotic and non-antibiotic segments with specific departments for the domestic markets, other emerging markets and regulated markets. A specialised veterinary formulations program is also underway.
New Drug DiscoveryOrchid's strong NDD pipeline encompasses high-growth therapeutic segments like anti-diabetic, oncology among others. Orchid’s multi-therapeutic, multi-lead portfolio and selective partnerships with global customers for R&D projects reflects its emergence in the global drug discovery space as a potential player. Orchid’s R&D stands out in the drug discovery domain with the right mix of infrastructure, knowledge and business orientation, with faster decision making and execution excellence, re-enforcing its position as a preferred partner.
The infrastructure comprises of independent laboratories for medicinal chemistry, analytical chemistry, molecular modeling, pharmacology & pharmacokinetics and molecular biology. Lead molecules have been identified in two therapeutic areas – anti-infectives and pain management – based on confirmatory microbiological and pharmacological studies. Pre-formulation and other studies are also in progress for further lead optimisation. Furthermore, our medicinal chemistry division has well trained scientists who perform design and synthesis of novel molecules in various therapeutic areas such as anti-infectives, anti-inflammatory, anti-cancer and metabolic disorders. They interact with the drug design group to synthesise second-generation patentable molecules that are either inspired by natural products or successfully marketed in these therapeutic areas.
Pre-Clinical ResearchOur pre-clinical facility (PCF) undertakes a wide range of studies, including regulatory toxicity – which are required for filing Investigational New Drug (IND) applications. A number of new screening facilities and biological evaluation models have been set up to support the drug discovery and development process.
A wide range of animal toxicology, microbiology and pharmacology studies are also undertaken to confirm the safety and efficacy of molecules. The facility is registered with the committee for the Purpose of Control and Supervision of Experiment on Animals (CPCSEA), Ministry of Environment & Forests and the Government of India. Additionally, an Institutional Animal Ethics Committee (IAEC) monitors our research for issues related to animal welfare and experimentation. Work quality standards are in compliance with US Food Drug Administration (US FDA) and the Organisation for Economic Co-operation Development (OECD) principles of Good Laboratory Practice (GLP).
New Drug Delivery SystemsPioneering research to devise newer strategies for effectively delivering the drugs in the body or improvise the existing technologies to enhance their efficiency is the need of the hour. The ever improving delivery systems are not only beneficial to the patients as they are less cumbersome and easy to abide by but also reduce the complications associated with the induction of the drug in the body. At Orchid, we focus on developing novel drug delivery systems (NDDS) for select anti-infective molecules. A few platform and product specific technologies with six prototype formulations have been successfully developed.
Areas of NDDS Research Drug specific Platform technologies Disease conditions
Biotech ResearchOur biotech research is focused on replacing existing chemical methods of manufacturing various intermediates, with fermentation and enzymatic based transformations to improve environmental safety.
Capabilities include:
PCR and Directed evolution of proteins Gene cloning Protein expression and purification High-throughput screening Development of assays for proteins in the cephalosporin pathway
Intellectual Property ManagementWe have been a leading generator of intellectual property in the Indian pharmaceutical industry. The IPM department supports development of patent applications, files patents, supports the development of patent applications and identifies potential new products and markets for APIs and formulations besides supporting research activities. Orchid's Intellectual Property Management (IPM) department comprise of qualified and experienced personnel to support its operations.
Several filings have been made in the areas of new drug discovery (NDD) and novel drug delivery systems (NDDS) across various national and international patent offices. Several patents have been published and granted in the areas of drug discovery and other cutting-edge spaces. In
the near future, further acceleration in the filing process with the publication and grant of patents is expected.
CRAMS (Contract Research and Manufacturing Services)We have distinctively and rapidly evolved into a fully integrated Indian pharmaceutical Company, straddling the pharmaceutical chain with its presence in all six clusters of APIs, CRAMS, branded generics, regulated generics, NDDS (Novel Drug Delivery Systems) and NCEs (New Chemical Entities). Leveraging our world-class R&D base, we have taken up Contract Research and Manufacturing Services (CRAMS) as a discrete initiative and advanced, especially in the areas related to new drug products, NDDS and NCEs.
Over the years, Orchid Research's continuous investment in research and manufacture has positioned it as a global CRAMS partner. This initiative connects Orchid Research's discovery capabilities with the group's industrial-scale manufacturing capabilities.
As a result, Orchid Research centrally positions itself in the drug discovery domain with the right mix of infrastructure, knowledge and business orientation. With CRAMS, we also reinforce our position as a preferred global partner with the potential to undertake a wide range of projects on a 'FTE' or 'fee for service' basis.
Our service value proposition includes Offering dedicated teams and manufacturing lines for full-scale commercial manufacture
Leveraging resident drug discovery experience in multi-therapeutic and multi-lead discovery programmes
Providing business flexibility with early phase to proof-of-concept collaboration, enabling contract research and development projects across multiple domains
Scaling chemical development to a technologically efficient and cost-effective manner through the intelligent use of process optimisation and CMC (chemistry, manufacturing and controls) skills
Investing ethical values in our business activities, reflected in important knowledge protection initiatives and building walls to teams working for partner companies and protecting intellectual property
Manufacturing lab-scale, pre-clinical and clinical scale supplies
In this domain, we have master service agreements with Pfizer, covering both animal health and human health applications, under the aegis of which several projects have been either executed or currently in the pipeline. We are in discussions with other innovator firms for contract research and manufacturing agreements.
Spirit of Orchid!At Orchid, human resources are our most valuable asset. We take an entrepreneurial approach that urges high performance standards from our employees through collaborative management. Over the years, our research products and initiatives have touched generations of people in India and abroad. We started commercial operations in 1994 and today we have reached a stage, which facilitates enhanced value creation. The company as a whole represents a synergy of active talent at work, in generating remarkable performance with a single-minded commitment to produce extraordinary results and achieve the highest standards of quality in all spheres.
Experts say 'quite an achievement', but we differ. We call it the 'Orchidian spirit' - the spirit that inspires 4000 plus people to challenge conventions, break with the past, work better, try harder and grow bigger. At Orchid, no matter what the odds, we believe in the dictum: tough times don’t last, tough people do. In short, make a difference each day to the life we lead, the organisation we work for, the nation we are proud of and the planet we live in.
Our Secret IngredientsOur remarkable growth across multiple therapies and geographies is primarily driven by an empowered culture to experiment, innovate and perform. Our core values of respect for human resource and empowerment have emerged as a unique cohesive force, complementing established and new skill-sets with an integrated, motivated organisation. We try to create an organisation wherein you put all the warmth, affection and care and what you get in return is excellence in all forms.
Work Environment
Here at Orchid, we offer an environment where growth is based on the ability to contribute, perform and achieve – focus is to bring out your best strengths. We are proud to celebrate our people – people trying harder, people taking risks, people making breakthrough innovations, people breaking barriers to collaborate, people determined to prove a point. Walk around our workspaces and you will feel the positive energy. Minds are constantly in motion – researching, innovating and creating ideas. It is this mindset, which sets us apart.
Diversity and inclusionDiversity is one of our special ingredients for success. We believe diversity is essential for building an enriching work environment. We include everyone and exclude no one. People from all parts of the world with different backgrounds are welcomed at the workplace. We encourage people to set their own goals in order to achieve excellence. Within our common purpose, we encourage people to embrace their individuality and grow.
Work-Life balanceSuccess is achieved when one finds the right balance between the demands on the professional front and the accomplishment of personal goals. We, at Orchid try to create that flexible environment for our people in the way we work and the things we do.
Why become an Orchidian?We provide our employees a dynamic, professional environment bound by one spirit – The 'Orchidian Spirit' – which makes Orchid a great place to work. Our defined set of values and culture reflects our shared accountability for business goals, our aggressiveness in pursuing these goals, ways to achieve these goals and our adaptability in finding new and better products. We offer a host of career opportunities in all aspects of pharmaceutical research, manufacturing and marketing as well as corporate support functions.
It is the people here who bring about the positive difference in the quest towards achieving higher levels of growth and profitability in the years to come.
OpportunitiesWe constantly encourage our employees to raise the bar, extend the limit. Our people handle multiple responsibilities and stretch the limits of what is possible and what is not. We keep our people intellectually stimulated and give them the freedom to make their own decisions, instilling in them a responsibility to help in the advancement of both the self and the company. At Orchid, there are several programmes offered to employees with opportunities to acquire and develop functional, people management and decision-making skills, enabling success at work.
Grow with UsTo us, our people are the key drivers of our success. Our commitment to training and development is a core value. That is why we invest greatly in training and development, both on and off the job, for the continuous enhancement of knowledge, skills and capabilities of our employees. As we grow, so do our people, developing new capabilities to take our business ahead.
We would be pleased to have your resume on file for any available positions and will review it should an opening arise.